TSE:4568Pharmaceuticals
How General Proximity Partnership and STING Agonist Trial Will Impact Daiichi Sankyo (TSE:4568) Investors
On November 12, 2025, General Proximity announced a multi-target collaboration with Daiichi Sankyo's Boston Research Institute to apply its OmniTAC platform to discover new oncology therapies, while Daiichi Sankyo also recently commenced a first-in-human trial for its STING agonist ADC, DS3610, in advanced solid tumors.
This collaboration highlights the industry's increased focus on induced proximity medicines and Daiichi Sankyo's commitment to advancing treatments for challenging and...